INBRIJA

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania, Poland, United States

Active ingredients

The drug INBRIJA contains one active pharmaceutical ingredient (API):

1 Levodopa UNII 46627O600J - LEVODOPA

According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease. Read about Levodopa

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
INBRIJA Inhalation powder, capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N04BA01	Levodopa	N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BA Dopa and dopa derivatives
Discover more medicines within N04BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1802247, 1802258
Country: IT	Agenzia del Farmaco	Identifier(s): 048253013, 048253025
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1088511, 1088512
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100424346
Country: US	FDA, National Drug Code	Identifier(s): 10144-342